Quantitative analysis of persister fractions suggests different mechanisms of formation among environmental isolates of E. coli

BMC Microbiology

Olin K Silander¹  Erik van Nimwegen¹  Niels Hofsteenge¹ 

[1] Computational and Systems Biology, Biozentrum, University of Basel, Basel, Switzerland

关键词: E. coli;    Environmental isolates;    Nalidixic acid;    Ciprofloxacin;    Ampicillin;    Antibiotic;    Persister;   

Others  :  1144471
DOI  :  10.1186/1471-2180-13-25

 received in 2012-10-09, accepted in 2013-01-17,  发布年份 2013

【 摘 要 】

Background

Bacterial persistence describes a phenomenon wherein a small subpopulation of cells is able to survive a challenge with high doses of an antibiotic (or other stressor) better than the majority of the population. Previous work has shown that cells that are in a dormant or slow-growing state are persistent to antibiotic treatment and that populations with higher fractions of dormant cells exhibit higher levels of persistence. These data suggest that a major determinant of the fraction of persisters within a population is the rate at which cells enter and exit from dormancy. However, it is not known whether there are physiological changes in addition to dormancy that influence persistence. Here, we use quantitative measurements of persister fractions in a set of environmental isolates of E. coli together with a mathematical model of persister formation to test whether a single general physiological change, such as cell dormancy, can explain the differences in persister phenotypes observed in different strains.

Results

If a single physiological change (e.g. cell dormancy) underlies most persister phenotypes, then strains should exhibit characteristic fractions of persister cells: some strains will consistently have high fractions of persisters (dormant cells), whereas others will have low fractions. Although we found substantial variation in the fraction of persisters between different environmental isolates of E. coli, these fractions were not correlated across antibiotics. Some strains exhibited high persister fractions in one antibiotic, but low persister fractions in a second antibiotic. Surprisingly, no correlation in persister fractions was observed between any two drugs, even for antibiotics with nearly identical modes of action (ciprofloxacin and nalidixic acid).

Conclusions

These data support the hypothesis that there is no single physiological change that determines the persistence level in a population of cells. Instead, the fraction of cells that survive antibiotic treatment (persist) depends critically on the specific antibiotic that is used, suggesting that physiological changes in addition to dormancy can underlie persister phenotypes.

【 授权许可】

   
2013 Hofsteenge et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Bigger JW: Treatment of staphylococcal infections with penicillin - by intermittent sterilisation. Lancet 1944, 2:497-500.
• [2]del Pozo JL, Patel R: The challenge of treating biofilm-associated bacterial infection. Clin Pharmacol Ther 2007, 82(2):204-209.
• [3]Lewis K: Persister cells. Annu Rev Microbiol 2010, 64:357-372.
• [4]Mulcahy LR, Burns JL, Lory S, Lewis K: Emergence of pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 2010, 192(23):6191-6199.
• [5]Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A: The rate of killing of escherichia-coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial-growth. J Gen Microbiol 1986, 132:1297-1304.
• [6]Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S: Bacterial persistence as a phenotypic switch. Science 2004, 305(5690):1622-1625.
• [7]Keren I, Shah D, Spoering A, Kaldalu N, Lewis K: Specialized persister cells and the mechanism of multidrug tolerance in escherichia coli. J Bacteriol 2004, 186(24):8172-8180.
• [8]Shah D, Zhang ZG, Khodursky A, Kaldalu N, Kurg K, Lewis K: Persisters: a distinct physiological state of E-coli. BMC Microbiology 2006, 6:53. BioMed Central Full Text
• [9]Lewis K: Persister cells, dormancy and infectious disease. Nat Rev Microbiol 2007, 5(1):48-56.
• [10]Dorr T, Lewis K, Vulic M: SOS response induces persistence to fluoroquinolones in escherichia coli. PLoS Genet 2009, 5(12):e1000760.
• [11]Maisonneuve E, Shakespeare LJ, Jorgensen MG, Gerdes K: Bacterial persistence by RNA endonucleases. P Natl Acad Sci USA 2011, 108(32):13206-13211.
• [12]Moyed HS, Bertrand KP: Hipa, a newly recognized gene of escherichia-coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J Bacteriol 1983, 155(2):768-775.
• [13]Korch SB, Hill TM: Ectopic overexpression of wild-type and mutant hipA genes in escherichia coli: effects on macromolecular synthesis and persister formation. J Bacteriol 2006, 188(11):3826-3836.
• [14]Dhar N, McKinney JD: Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice. P Natl Acad Sci USA 2010, 107(27):12275-12280.
• [15]Singh R, Barry CE, Boshoff HIM: The three RelE homologs of mycobacterium tuberculosis have individual, drug-specific effects on bacterial antibiotic tolerance. J Bacteriol 2010, 192(5):1279-1291.
• [16]Keren I, Minami S, Rubin E, Lewis K: Characterization and transcriptome analysis of mycobacterium tuberculosis persisters. Mbio 2011, 2(3):e00100-11.
• [17]Belenky P, Collins JJ: Antioxidant strategies to tolerate antibiotics. Science 2011, 334(6058):915-916.
• [18]Stewart B, Rozen DE: Genetic variation for antibiotic persistence in escherichia coli. Evolution 2012, 66(3):933-939.
• [19]Wolfson JS, Hooper DC, Mchugh GL, Bozza MA, Swartz MN: Mutants of escherichia-coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents. Antimicrob Agents Ch 1990, 34(10):1938-1943.
• [20]Joers A, Kaldalu N, Tenson T: The frequency of persisters in escherichia coli reflects the kinetics of awakening from dormancy. J Bacteriol 2010, 192(13):3379-3384.
• [21]Luidalepp H, Joers A, Kaldalu N, Tenson T: Age of inoculum strongly influences persister frequency and Can mask effects of mutations implicated in altered persistence. J Bacteriol 2011, 193(14):3598-3605.
• [22]Foti JJ, Devadoss B, Winkler JA, Collins JJ, Walker GC: Oxidation of the guanine nucleotide pool underlies cell death by bactericidal antibiotics. Science 2012, 336(6079):315-319.
• [23]Wiuff C, Andersson DI: Antibiotic treatment in vitro of phenotypically tolerant bacterial populations. J Antimicrob Chemoth 2007, 59(2):254-263.
• [24]Spoering AL, Vulic M, Lewis K: GlpD and PlsB participate in persister cell formation in Eschetichia coli. J Bacteriol 2006, 188(14):5136-5144.
• [25]Hansen S, Lewis K, Vulic M: Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli. Antimicrob Agents Ch 2008, 52(8):2718-2726.
• [26]Ishii S, Ksoll WB, Hicks RE, Sadowsky MJ: Presence and growth of naturalized Escherichia coli in temperate soils from lake superior watersheds. Appl Environ Microb 2006, 72(1):612-621.
• [27]Luo CW, Walk ST, Gordon DM, Feldgarden M, Tiedje JM, Konstantinidis KT: Genome sequencing of environmental Escherichia coli expands understanding of the ecology and speciation of the model bacterial species. P Natl Acad Sci USA 2011, 108(17):7200-7205.
• [28]Oliphant CM, Green GM: Quinolones: a comprehensive review. Am Fam Physician 2002, 65(3):455-464.
• [29]Correia FF, D’Onofrio A, Rejtar T, Li LY, Karger BL, Makarova K, Koonin EV, Lewis K: Kinase activity of overexpressed HipA is required for growth arrest and multidrug tolerance in Escherichia coli. J Bacteriol 2006, 188(24):8360-8367.
• [30]Vazquez-Laslop N, Lee H, Neyfakh AA: Increased persistence in Escherichia coli caused by controlled expression of toxins or other unrelated proteins. J Bacteriol 2006, 188(10):3494-3497.
• [31]Hooper DC, Wolfson JS: Mode of action of the New quinolones - New data. Eur J Clin Microbiol 1991, 10(4):223-231.
• [32]Jacoby GA: Mechanisms of resistance to quinolones. Clin Infect Dis 2005, 41:S120-S126.
• [33]Silander OK, Ackermann M: The constancy of gene conservation across divergent bacterial orders. BMC Research Notes 2009, 2:2. BioMed Central Full Text
• [34]Johnson PJT, Levin BR: Pharmacodynamics, population dynamics and the evolution of persistence in staphylococcus aureus. PLoS Genet 2013. in press
• [35]Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, Levin BR: Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Ch 2004, 48(10):3670-3676.
• [36]Gefen O, Gabay C, Mumcuoglu M, Engel G, Balaban NQ: Single-cell protein induction dynamics reveals a period of vulnerability to antibiotics in persister bacteria. P Natl Acad Sci USA 2008, 105(16):6145-6149.
• [37]Kashiwagi K, Tsuhako MH, Sakata K, Saisho T, Igarashi A, da Costa SOP, Igarashi K: Relationship between spontaneous aminoglycoside resistance in Escherichia coli and a decrease in oligopeptide binding protein. J Bacteriol 1998, 180(20):5484-5488.
• [38]Levin-Reisman I, Gefen O, Fridman O, Ronin I, Shwa D, Sheftel H, Balaban NQ: Automated imaging with ScanLag reveals previously undetectable bacterial growth phenotypes. Nat Methods 2010, 7(9):737-U100.
• [39]R: a language and environment for statistical computing. http://www.R-project.org webcite